Pulse Biosciences stockholders approve equity plan amendment and ratify director options

PULSE BIOSCIENCES, INC.

Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.
Ratified options for up to 1.1 million shares, including 600,000 to directors (CEO LaViolette).
Director options have exercise price $15.65, 10-year term, vesting over annual meeting and monthly.
Proposal 1 voted 50,247,945 For vs 2,753,901 Against; Proposal 2 similarly approved.
Special Meeting held Sept 30, 2025; quorum of 53,011,701 shares represented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.